Aggressive Medical Treatment With or Without Stenting in High-Risk Patients With Intracranial Artery Stenosis (Sammpris): The Final Results of a Randomised Trial
Background Early results of the Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis trial showed that, by 30 days, 33 (14Â·7%) of 224 patients in the stenting group and 13 (5Â·8%) of 227 patients in the medical group had died or had a stroke (percentages are product limit estimates), but provided insufficient data to establish whether stenting offered any longer-term benefit. Here we report the long-term outcome of patients in this trial. Methods We randomly assigned (1:1, stratified by centre with randomly permuted block sizes) 451 patients with recent transient ischaemic attack or stroke related to 70-99% stenosis of a major intracranial artery to aggressive medical management (antiplatelet therapy, intensive management of vascular risk factors, and a lifestyle-modification programme) or aggressive medical management plus stenting with the Wingspan stent. The primary endpoint was any of the following: stroke or death within 30 days after enrolment, ischaemic stroke in the territory of the qualifying artery beyond 30 days of enrolment, or stroke or death within 30 days after a revascularisation procedure of the qualifying lesion during follow-up. Primary endpoint analysis of between-group differences with log-rank test was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT 00576693. Findings During a median follow-up of 32Â·4 months, 34 (15%) of 227 patients in the medical group and 52 (23%) of 224 patients in the stenting group had a primary endpoint event. The cumulative probability of the primary endpoints was smaller in the medical group versus the percutaneous transluminal angioplasty and stenting (PTAS) group (p=0Â·0252). Beyond 30 days, 21 (10%) of 210 patients in the medical group and 19 (10%) of 191 patients in the stenting group had a primary endpoint. The absolute differences in the primary endpoint rates between the two groups were 7Â·1% at year 1 (95% CI 0Â·2 to 13Â·8%; p=0Â·0428), 6Â·5% at year 2 (-0Â·5 to 13Â·5%; p=0Â·07) and 9Â·0% at year 3 (1Â·5 to 16Â·5%; p=0Â·0193). The occurrence of the following adverse events was higher in the PTAS group than in the medical group: any stroke (59 [26%] of 224 patients vs 42 [19%] of 227 patients; p=0Â·0468) and major haemorrhage (29 [13%] of 224 patients vs 10 [4%] of 227 patients; p=0Â·0009). Interpretation The early benefit of aggressive medical management over stenting with the Wingspan stent for highrisk patients with intracranial stenosis persists over extended follow-up. Our findings lend support to the use of aggressive medical management rather than PTAS with the Wingspan system in high-risk patients with atherosclerotic intracranial arterial stenosis. Funding National Institute of Neurological Disorders and Stroke (NINDS) and others.
Medical Subject Headings
Digital Object Identifier (DOI)
Derdeyn, Colin P.; Chimowitz, Marc I.; Lynn, Michael J.; Fiorella, David; Turan, Tanya N.; Janis, L. Scott; Montgomery, Jean; Nizam, Azhar; Lane, Bethany F.; Lutsep, Helmi L.; Barnwell, Stanley L.; Waters, Michael F.; Hoh, Brian L.; Hourihane, J. Maurice; Levy, Elad I.; Alexandrov, Andrei V.; Harrigan, Mark R.; Chiu, David; Klucznik, Richard P.; and al., et, "Aggressive Medical Treatment With or Without Stenting in High-Risk Patients With Intracranial Artery Stenosis (Sammpris): The Final Results of a Randomised Trial" (2014). Neurology. 289.